UK Epigenetics Market Size & Outlook, 2023-2030

The epigenetics market in UK is expected to reach a projected revenue of US$ 3,381.4 million by 2030. A compound annual growth rate of 18.4% is expected of UK epigenetics market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,034.4
Forecast, 2030 (US$M)
$3,381.4
CAGR, 2024 - 2030
18.4%
Report Coverage
UK

UK epigenetics market highlights

  • The UK epigenetics market generated a revenue of USD 1,034.4 million in 2023 and is expected to reach USD 3,381.4 million by 2030.
  • The UK market is expected to grow at a CAGR of 18.4% from 2024 to 2030.
  • In terms of segment, reagents was the largest revenue generating product in 2023.
  • Services is the most lucrative product segment registering the fastest growth during the forecast period.


Epigenetics market data book summary

Market revenue in 2023USD 1,034.4 million
Market revenue in 2030USD 3,381.4 million
Growth rate18.4% (CAGR from 2023 to 2030)
Largest segmentReagents
Fastest growing segmentServices
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationReagents, Kits, Instruments, Enzymes, Services
Key market players worldwideRoche Holding AG, Thermo Fisher Scientific Inc, Eisai Co Ltd, Novartis AG ADR, Element Biosciences, Dovetail Genomics, Illumina Inc, Promega, Abcam PLC


Other key industry trends

  • In terms of revenue, UK accounted for 7.1% of the global epigenetics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany epigenetics market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 3,381.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Epigenetics Market Companies

Name Profile # Employees HQ Website

UK epigenetics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epigenetics market will help companies and investors design strategic landscapes.


Reagents was the largest segment with a revenue share of 32.82% in 2023. Horizon Databook has segmented the UK epigenetics market based on reagents, kits, instruments, enzymes, services covering the revenue growth of each sub-segment from 2018 to 2030.


The UK epigenetics market is a rapidly growing industry that is expected to witness significant growth in the forecast years. The growth of the UK epigenetics market is driven by robust research and innovation in genetic & molecular studies, coupled with supportive government initiatives and a strong healthcare infrastructure that fosters advancements in epigenetic research.

According to an article published in November 2023 by the Imperial College Healthcare NHS Trust, the UK's approval of gene editing therapy, specifically the CRISPR-based Casgevy, marks a milestone with potential implications for the UK epigenetics market.

As the first country to authorize such therapy for inherited blood disorders, the UK's regulatory approval signifies a pivotal step in integrating advanced gene editing tools into clinical practice, with the potential to influence & shape the landscape of the UK epigenetics market by opening new avenues for research and therapeutic applications.

Reasons to subscribe to UK epigenetics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK epigenetics market databook

  • Our clientele includes a mix of epigenetics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK epigenetics market , including forecasts for subscribers. This country databook contains high-level insights into UK epigenetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK epigenetics market size, by product, 2018-2030 (US$M)

UK Epigenetics Market Outlook Share, 2023 & 2030 (US$M)

UK epigenetics market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more